On September 16, 2025 NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, reported that the company’s abstract featuring first clinical data from its ongoing Phase I/II trial has been selected for an oral presentation at the European Association of Nuclear Medicine (EANM) congress, taking place from October 4 – 8, 2025 in Barcelona, Spain (Press release, NUCLIDIUM, SEP 16, 2025, View Source [SID1234655999]). The Phase I/II trial is evaluating the company’s PET tracer, 61Cu-TraceNetTM [61Cu]Cu-NODAGA-LM3 for the detection of SSTR-positive gastroenteropancreatic & bronchopulmonary neuroendocrine tumors (GEP & BP-NETS). Dr. Guillaume Nicolas, Deputy Head of Nuclear Medicine at the Department of Theragnostics, University Hospital Basel, Switzerland, and principal investigator of the study, will present the data.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation Details
Session Title: Clinical Oncology Track – Top Rated Oral Presentation – Oncology & Theranostics Committee: NET Imaging
Abstract Title: "A phase I/II study of [61Cu]Cu -NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET Trial"
Date and Time: Monday, October 6, 2025, at 9:45 AM CEST
Location: Barcelona International Convention Centre Room 117